Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 7OTHER 5NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 5Neuroblastoma 4Ganglioneuroblastoma 4Breast Neoplasms 4Prostatic Neoplasms 3Medulloblastoma 3Wilms Tumor 2Teratoma 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Rhabdomyosarcoma, Embryonal 2Rhabdomyosarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Mouth Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Embryonal 2Carcinoma 2Burkitt Lymphoma 2Astrocytoma 2Uterine Cervical Neoplasms 1Stage I Mixed Cell Type Kidney Wilms Tumor 1Seizures 1Sarcoma, Ewing 1Rhabdomyosarcoma, Alveolar 1

Interventions

Vincristine 17Cyclophosphamide 17Cytarabine 16Methotrexate 14Doxorubicin 14Prednisone 11Etoposide 11Radiotherapy 10merphos 9Rituximab 8Dexamethasone 8pegaspargase 7Leucovorin 7Filgrastim 7Calcium Dobesilate 7Methylprednisolone 6Daunorubicin 6dexamethasone acetate 5dexamethasone 21-phosphate 5calaspargase pegol 5azathiopurine 5auricularum 5Thioguanine 5Mercaptopurine 5Hydrocortisone 5Granulocyte Colony-Stimulating Factor 5Asparaginase 5prednylidene 4deltacortene 4Specimen Handling 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Burkitt Lymphoma × Magnetic Resonance Spectroscopy × Clear all
NCT03504644 2026-05-29

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Eastern Cooperative Oncology Group

Phase 1/2 Active not recruiting
40 enrolled 18 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡